Maxim Group analyst Michael Okunewitch has maintained their bullish stance on FBLG stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Michael Okunewitch has given his Buy rating due to a combination of factors that highlight FibroBiologics, Inc.’s promising potential in the regenerative medicine field. The company is advancing its wound care cell therapy, CYWC628, which is poised to enter clinical trials in the third quarter of 2025. This therapy targets diabetic foot ulcers, a significant market opportunity given the high prevalence and healthcare costs associated with chronic wounds.
Furthermore, FibroBiologics is leveraging the unique properties of fibroblasts, which are abundant and cost-effective compared to stem cells, making them an attractive option for cell therapy. The company’s preclinical studies have shown that their fibroblast-based therapy can significantly accelerate wound healing, outperforming existing market-leading products. Additionally, the potential application of fibroblasts in treating inflammatory conditions like psoriasis, which represents a large market, further supports the positive outlook for the company’s future growth and development.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.